Skip to Content

IGM Biosciences Inc Ordinary Shares IGMS

Morningstar Rating
$9.65 +0.38 (4.10%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

IGMS is trading at a 62% discount.
Price
$8.77
Fair Value
$28.18
Uncertainty
Extreme
1-Star Price
$851.19
5-Star Price
$3.70
Economic Moat
Hlpl
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if IGMS is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$9.27
Day Range
$9.209.71
52-Week Range
$3.8117.78
Bid/Ask
$10.26 / $10.88
Market Cap
$567.29 Mil
Volume/Avg
244,280 / 304,086

Key Statistics

Price/Earnings (Normalized)
Price/Sales
237.00
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

IGM Biosciences Inc is a biotechnology company engaged in the development of IgM antibody therapeutics for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. Its IgM antibody technology platform is suited for developing T cell engagers, receptor cross-linking agonists, and targeted cytokines. Its product candidate, Aplitabart: An IgM antibody targeting Death Receptor 5 (DR5) proteins, for the treatment of colorectal cancer; Imvotamab: A bispecific for severe systemic lupus erythematosus (SLE) and one for severe rheumatoid arthritis (RA); and IGM-2644: A bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins, currently planned for evaluation in autoimmune disease.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Value
Total Number of Employees
224

Comparables

Valuation

Metric
IGMS
MRSN
CLDX
Price/Earnings (Normalized)
Price/Book Value
2.7914.655.45
Price/Sales
237.0014.11294.86
Price/Cash Flow
Price/Earnings
IGMS
MRSN
CLDX

Financial Strength

Metric
IGMS
MRSN
CLDX
Quick Ratio
7.953.2913.69
Current Ratio
8.183.3613.87
Interest Coverage
−44.11
Quick Ratio
IGMS
MRSN
CLDX

Profitability

Metric
IGMS
MRSN
CLDX
Return on Assets (Normalized)
−44.52%−49.57%−30.49%
Return on Equity (Normalized)
−84.37%−211.52%−33.19%
Return on Invested Capital (Normalized)
−77.23%−146.81%−32.85%
Return on Assets
IGMS
MRSN
CLDX
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
NVO
Novo Nordisk A/S ADRFclysprbfnLjtqt$570.1 Bil
VRTX
Vertex Pharmaceuticals IncQsvwntrQyrbww$108.0 Bil
REGN
Regeneron Pharmaceuticals IncFywxwrbdGnqdp$105.6 Bil
MRNA
Moderna IncVmqhbcmbMpqsq$40.8 Bil
ARGX
argenx SE ADRZzxcktnqDzzf$23.7 Bil
BNTX
BioNTech SE ADRSghznbrwJpnmp$21.9 Bil
ALNY
Alnylam Pharmaceuticals IncHsjvvxkqFqrth$18.8 Bil
BMRN
Biomarin Pharmaceutical IncYbwkfbmQzwcbs$16.5 Bil
RPRX
Royalty Pharma PLC Class ABmxngwjkdKwdbrvn$13.6 Bil
INCY
Incyte CorpMjczgpytHsjxs$12.8 Bil

Sponsor Center